Genmab — Maj 2019
-
-
Relax...Glimrende spørgsmål til Q&A.
-
Skyd bare løs.
-
-
Super.
-
Husk det skal være på engelsk.
-
-
E L with the new DKd arm in the phase II kombination study with sc dara it for sure now must be only filing for mono sc dosing this year - and then probably first combination filing next year and if we are unlucky approval in early 2021 for sc dosing in combination
-
Medicin til 13 mio kr per behandling rammer markedet i USA
En genterapi til muskelsvind hos spædbørn tegner til at tage rekorden for den hidtil dyreste behandling på det amerikanske marked med i pris i omegnen af to mio. dollar.
(medwatch.dk)
-
-
A new study appearing in Leukemia Research from researchers at the Institute for Myeloma & Bone Cancer Research seeking to better understand the phenomenon evaluated 379 samples from relapsed/refractory MM patients and found elevated levels soluble BCMA that were associated with reduced binding by an inhibitory antibody. The group thus suggested that free-floating protein act as a “decoys” that may contribute to diminished efficacy of anti-BCMA therapies.
-
One possible solution to the issue of circulating BCMA that has been proposed is to combine a direct antagonist, be it a CAR-T construct or antibody-based therapy, with an inhibitor of gamma secretase, an enzyme that cleaves transmembrane proteins and is believes to lead to increased levels of soluble BCMA.
we anticipate regulatory submissions by ENHANZEHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind